Pipeline & Upcoming Peptides
Peptide drugs currently in clinical trials or awaiting FDA approval. These represent the next generation of peptide therapeutics, including triple agonists, oral formulations, and novel targets.
All Pipeline & Upcoming Peptides (2)
Retatrutide
In Clinical TrialsGLP-1 Receptor Agonists
Retatrutide is an investigational triple-action peptide that activates GLP-1, GIP, and glucagon receptors simultaneously. In Phase 2 trials, it produc...
Obesity treatmentType 2 diabetesNASH/MAFLD
SS-31
In Clinical TrialsMitochondrial Peptides
SS-31 (elamipretide) is a mitochondria-targeted peptide that concentrates 1000-fold in the inner mitochondrial membrane. It protects mitochondrial fun...
Mitochondrial protectionHeart failureAge-related decline
Comparison Table
| Peptide | Legal Status (USA) | Evidence | Administration | Half-Life | Primary Uses |
|---|---|---|---|---|---|
| Retatrutide | In Clinical Trials | B | subcutaneous | ~6 days | Obesity treatmentType 2 diabetes+1 |
| SS-31 | In Clinical Trials | B | subcutaneous, intravenous | ~3-4 hours | Mitochondrial protectionHeart failure+2 |